Literature DB >> 28609317

Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.

Taro Tomizuka1, Kenjiro Namikawa, Takahiro Higashi.   

Abstract

The distribution and incidence of melanoma vary among different races and ethnic groups. This study aimed to investigate the characteristics of cutaneous melanoma, mucosal melanoma, uveal melanoma, and melanoma of unknown primary (MUP) origin in a Japanese population. We studied these four types of melanoma in patients registered in Hospital Based Cancer Registries in Japan from 2011 to 2013. A total of 5566 patients with melanoma were identified. The distribution of sex, age, primary site, and clinical stage was analyzed. The number of patients, proportion in comparison with all melanoma cases, and crude incidence rate per 100 000 person-year of each melanoma type were 4481, 80.5%, and 1.24 in invasive cutaneous; 821, 14.8%, and 0.32 in mucosal; 163, 2.9%, and 0.064 in uveal; and 101, 1.8%, and 0.039 in MUP origin, respectively. Including the patients with in-situ cutaneous melanoma and stage unknown cutaneous melanoma, the crude incidence rate of cutaneous melanoma increased at 1.75. Almost half of the cutaneous melanomas were located in the lower limb. Cutaneous melanoma was the most common, but less frequent than that in western countries. Mucosal melanoma was quite rare, but its proportion and crude incidence rate were higher than those in western countries. Uveal melanoma was particularly rare, and its crude incidence rate was lower than that in western countries. MUP origin was also particularly rare, but it had almost the same incidence rate as that in other countries. Melanoma in Japan was heterogeneous among the four melanoma types and shares some attributes with that in western countries.

Entities:  

Mesh:

Year:  2017        PMID: 28609317     DOI: 10.1097/CMR.0000000000000375

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  22 in total

1.  Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017.

Authors:  A F Bais; R M Lucas; J F Bornman; C E Williamson; B Sulzberger; A T Austin; S R Wilson; A L Andrady; G Bernhard; R L McKenzie; P J Aucamp; S Madronich; R E Neale; S Yazar; A R Young; F R de Gruijl; M Norval; Y Takizawa; P W Barnes; T M Robson; S A Robinson; C L Ballaré; S D Flint; P J Neale; S Hylander; K C Rose; S-Å Wängberg; D-P Häder; R C Worrest; R G Zepp; N D Paul; R M Cory; K R Solomon; J Longstreth; K K Pandey; H H Redhwi; A Torikai; A M Heikkilä
Journal:  Photochem Photobiol Sci       Date:  2018-02-14       Impact factor: 3.982

Review 2.  Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Authors:  Hiroyuki Goto; Yoshio Kiyohara; Masahisa Shindo; Osamu Yamamoto
Journal:  Curr Treat Options Oncol       Date:  2019-03-27

3.  Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

Authors:  T M Petrella; G G Fletcher; G Knight; E McWhirter; S Rajagopal; X Song; T D Baetz
Journal:  Curr Oncol       Date:  2020-02-01       Impact factor: 3.677

4.  Incidence and Survival Rates of Cutaneous Melanoma in South Korea Using Nationwide Health Insurance Claims Data.

Authors:  TaeHo Kim; Siyeong Yoon; Dong-Eun Shin; Sang Cheol Lee; Jisu Oh; So-Young Lee; Do Kyung Kim; Segi Kim; Bosung Jung; Minsup Kim; Soonchul Lee
Journal:  Cancer Res Treat       Date:  2021-09-30       Impact factor: 5.036

5.  Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.

Authors:  Naoya Yamazaki; Yoshio Kiyohara; Hisashi Uhara; Jiro Uehara; Yasuhiro Fujisawa; Tatsuya Takenouchi; Masaki Otsuka; Hiroshi Uchi; Hironobu Ihn; Masahiro Hatsumichi; Hironobu Minami
Journal:  Cancer Sci       Date:  2019-05-23       Impact factor: 6.716

6.  Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.

Authors:  Yasuhiro Fujisawa; Shusuke Yoshikawa; Akane Minagawa; Tatsuya Takenouchi; Kenji Yokota; Hiroshi Uchi; Naoki Noma; Yasuhiro Nakamura; Jun Asai; Junji Kato; Susumu Fujiwara; Satoshi Fukushima; Jiro Uehara; Toshihiko Hoashi; Tatsuya Kaji; Taku Fujimura; Kenjiro Namikawa; Manabu Yoshioka; Naoki Murao; Dai Ogata; Kanako Matsuyama; Naohito Hatta; Yoshitsugu Shibayama; Toshiharu Fujiyama; Masashi Ishikawa; Daisuke Yamada; Akiko Kishi; Yoshiyuki Nakamura; Takatoshi Shimiauchi; Kazuyasu Fujii; Manabu Fujimoto; Hironobu Ihn; Norito Katoh
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

Review 7.  Targeted Therapy and Immunotherapy for Melanoma in Japan.

Authors:  Kenjiro Namikawa; Naoya Yamazaki
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

Review 8.  Uveal Melanoma in Asians: A Review.

Authors:  Pradeep Manchegowda; Arun D Singh; Carol Shields; Swathi Kaliki; Parag Shah; Lingam Gopal; Pukhraj Rishi
Journal:  Ocul Oncol Pathol       Date:  2021-02-09

9.  Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?

Authors:  Tsuyoshi Muta
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

10.  Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.

Authors:  Kenjiro Namikawa; Yoshio Kiyohara; Tatsuya Takenouchi; Hisashi Uhara; Hiroshi Uchi; Shusuke Yoshikawa; Sumiko Takatsuka; Hiroshi Koga; Naoko Wada; Hironobu Minami; Masahiro Hatsumichi; Yoshinobu Namba; Naoya Yamazaki
Journal:  J Dermatol       Date:  2020-08-18       Impact factor: 4.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.